MITF and melanoma: There are many questions regarding the rationale and execution of this strategy, including how methotrexate induces MITF expression, how to reconcile the known oncogenic role of MITF in melanoma to further increase its expression, and how targeting DHFR—a long explored target in cancer—could overcome the acquired resistance long associated with methotrexate.